Novartis Reports Results of Kesimpta (ofatumumab) in P- III ASCLEPIOS Trials for Newly Diagnosed Patients with RMS
Novartis Entered into a Collaboration and License Agreement with Dunad to Develop Oral Targeted Protein Degrader Therapies
Shots:
- The company reported new post hoc data from the P- III ASCLEPIOS trials assessing Kesimpta (ofatumumab) vs teriflunomide in a subgroup of newly diagnosed, treatment-naïve patients with RMS
- The results showed a 60% reduction in the risk of disability progression independent of relapse activity @3 and 6 mos., thus supporting Kesimpta as a 1L treatment option for adults with RMS. The data is presented at AAN2021
- Emerging OLE study data from the ALITHIOS trial showed that Kesimpta precisely delivered through SC administration, mean serum IgM/IgG levels remained within the reference ranges over a 3yrs. period to Dec 2020
Click here to read full press release/ article | Ref: Novartis | Image: BioProcess International